Cargando…
Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019
BACKGROUND: There is considerable variation in reported chronic obstructive pulmonary disease (COPD) prevalence internationally, partly due to differing definitions in use. Accurate estimates of disease prevalence are important for allocation of health-care resources, yet UK estimates of COPD preval...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368107/ https://www.ncbi.nlm.nih.gov/pubmed/37497381 http://dx.doi.org/10.2147/COPD.S411739 |
_version_ | 1785077444367089664 |
---|---|
author | Stone, Philip W Osen, Michael Ellis, Andrew Coaker, Rebecca Quint, Jennifer K |
author_facet | Stone, Philip W Osen, Michael Ellis, Andrew Coaker, Rebecca Quint, Jennifer K |
author_sort | Stone, Philip W |
collection | PubMed |
description | BACKGROUND: There is considerable variation in reported chronic obstructive pulmonary disease (COPD) prevalence internationally, partly due to differing definitions in use. Accurate estimates of disease prevalence are important for allocation of health-care resources, yet UK estimates of COPD prevalence have not been updated for a decade. We calculated yearly COPD prevalence in England between 2000 and 2019 using different definitions of COPD. METHODS: We used routinely collected primary care electronic healthcare record (EHR) data from the Clinical Practice Research Datalink (CPRD) Aurum database linked with secondary care data from the Hospital Episode Statistics (HES) Admitted Patient Care (APC) database. Mid-year point prevalence was calculated yearly from 2000 to 2019 in English adults aged ≥40 years using 5 definitions: (i) validated COPD, (ii) Quality and Outcomes Framework (QOF) COPD, (iii) COPD symptoms, inhaler prescription, and no asthma diagnosis, (iv) hospitalisation with COPD as any diagnosis, (v) hospitalisation with COPD as primary or secondary diagnosis. Prevalence was further stratified by gender, age group, and region. RESULTS: A total of 12,745,793 people were included over the 20-year period. Annual cohort sizes ranged from 4,373,538 in 2000 to 6,159,496 in 2019. Estimates of COPD prevalence increased every year from 2000 and the difference in estimated prevalence between the validated and QOF definitions has grown over time. In 2019, a COPD prevalence of 4.9% was found using validated events in either primary or secondary care (definition 1 or definition 5). Additionally, including potentially undiagnosed cases (definition 3) in the COPD definition produced an increased prevalence of 6.7%. CONCLUSION: Common definitions of COPD (eg, QOF codes), may underestimate the true prevalence. The extent of this underestimate has increased over time and could lead to under-allocation of resources where need is estimated based on these definitions. Standardisation of COPD coding in routine EHRs and metrics such as spirometry is key to accurate disease monitoring. |
format | Online Article Text |
id | pubmed-10368107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-103681072023-07-26 Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 Stone, Philip W Osen, Michael Ellis, Andrew Coaker, Rebecca Quint, Jennifer K Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: There is considerable variation in reported chronic obstructive pulmonary disease (COPD) prevalence internationally, partly due to differing definitions in use. Accurate estimates of disease prevalence are important for allocation of health-care resources, yet UK estimates of COPD prevalence have not been updated for a decade. We calculated yearly COPD prevalence in England between 2000 and 2019 using different definitions of COPD. METHODS: We used routinely collected primary care electronic healthcare record (EHR) data from the Clinical Practice Research Datalink (CPRD) Aurum database linked with secondary care data from the Hospital Episode Statistics (HES) Admitted Patient Care (APC) database. Mid-year point prevalence was calculated yearly from 2000 to 2019 in English adults aged ≥40 years using 5 definitions: (i) validated COPD, (ii) Quality and Outcomes Framework (QOF) COPD, (iii) COPD symptoms, inhaler prescription, and no asthma diagnosis, (iv) hospitalisation with COPD as any diagnosis, (v) hospitalisation with COPD as primary or secondary diagnosis. Prevalence was further stratified by gender, age group, and region. RESULTS: A total of 12,745,793 people were included over the 20-year period. Annual cohort sizes ranged from 4,373,538 in 2000 to 6,159,496 in 2019. Estimates of COPD prevalence increased every year from 2000 and the difference in estimated prevalence between the validated and QOF definitions has grown over time. In 2019, a COPD prevalence of 4.9% was found using validated events in either primary or secondary care (definition 1 or definition 5). Additionally, including potentially undiagnosed cases (definition 3) in the COPD definition produced an increased prevalence of 6.7%. CONCLUSION: Common definitions of COPD (eg, QOF codes), may underestimate the true prevalence. The extent of this underestimate has increased over time and could lead to under-allocation of resources where need is estimated based on these definitions. Standardisation of COPD coding in routine EHRs and metrics such as spirometry is key to accurate disease monitoring. Dove 2023-07-21 /pmc/articles/PMC10368107/ /pubmed/37497381 http://dx.doi.org/10.2147/COPD.S411739 Text en © 2023 Stone et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Stone, Philip W Osen, Michael Ellis, Andrew Coaker, Rebecca Quint, Jennifer K Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 |
title | Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 |
title_full | Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 |
title_fullStr | Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 |
title_full_unstemmed | Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 |
title_short | Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019 |
title_sort | prevalence of chronic obstructive pulmonary disease in england from 2000 to 2019 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368107/ https://www.ncbi.nlm.nih.gov/pubmed/37497381 http://dx.doi.org/10.2147/COPD.S411739 |
work_keys_str_mv | AT stonephilipw prevalenceofchronicobstructivepulmonarydiseaseinenglandfrom2000to2019 AT osenmichael prevalenceofchronicobstructivepulmonarydiseaseinenglandfrom2000to2019 AT ellisandrew prevalenceofchronicobstructivepulmonarydiseaseinenglandfrom2000to2019 AT coakerrebecca prevalenceofchronicobstructivepulmonarydiseaseinenglandfrom2000to2019 AT quintjenniferk prevalenceofchronicobstructivepulmonarydiseaseinenglandfrom2000to2019 |